Literature DB >> 1706731

Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis.

D Cohen1, M S Green, C Block, R Slepon, I Ofek.   

Abstract

A means for determining immune status against shigellosis would significantly improve the design and evaluation of interventional and other epidemiologic studies. Previous case-control studies have indicated the potential role of humoral antilipopolysaccharide antibodies. To test this proposition, 190 soldiers serving in a field unit were monitored prospectively for 2.5 months for shigellosis. Blood samples were taken at the beginning of the follow-up period and tested for serological evidence of prior exposure to Shigella sonnei and Shigella flexneri. The risk for acquiring S. sonnei shigellosis was 3.7 times higher for individuals lacking homologous antibodies (P less than 0.02). The risk for acquiring S. flexneri shigellosis was 2.4 times higher for individuals lacking antibodies, although a low attack rate for S. flexneri resulted in numbers too small to achieve statistical significance. While the importance of the serum antilipopolysaccharide antibodies in protection against the disease remains unclear, these findings demonstrate that they are strong markers of acquired immunity. Serological markers should be incorporated in epidemiologic studies of shigellosis and in the design and evaluation of future trials of potential anti-Shigella vaccines.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1706731      PMCID: PMC269772          DOI: 10.1128/jcm.29.2.386-389.1991

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  21 in total

1.  Studies in shigellosis. III. A controlled evaluation of a monovalent Shigella vaccine in a highly endemic environment.

Authors:  A R HIGGINS; T M FLOYD; M A KADER
Journal:  Am J Trop Med Hyg       Date:  1955-03       Impact factor: 2.345

2.  Immunoglobulin M, A, and G antibody response to lipopolysaccharide O antigen in symptomatic and asymptomatic Shigella infections.

Authors:  D Cohen; C Block; M S Green; G Lowell; I Ofek
Journal:  J Clin Microbiol       Date:  1989-01       Impact factor: 5.948

3.  Natural and recombinant interferons inhibit epithelial cell invasion by Shigella spp.

Authors:  D W Niesel; C B Hess; Y J Cho; K D Klimpel; G R Klimpel
Journal:  Infect Immun       Date:  1986-06       Impact factor: 3.441

4.  Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection.

Authors:  H L DuPont; R B Hornick; M J Snyder; J P Libonati; S B Formal; E J Gangarosa
Journal:  J Infect Dis       Date:  1972-01       Impact factor: 5.226

5.  Serum factors responsible for killing of Shigella.

Authors:  W P Reed; E L Albright
Journal:  Immunology       Date:  1974-01       Impact factor: 7.397

6.  The antibody response to bacterial gastroenteritis in serum and secretions.

Authors:  J T La Brooy; G P Davidson; D J Sherman; D Rowley
Journal:  Clin Exp Immunol       Date:  1980-08       Impact factor: 4.330

7.  Antibody-dependent cell-mediated antibacterial activity: K lymphocytes, monocytes, and granulocytes are effective against shigella.

Authors:  G H Lowell; R P MacDermott; P L Summers; A A Reeder; M J Bertovich; S B Formal
Journal:  J Immunol       Date:  1980-12       Impact factor: 5.422

8.  Protection against keratoconjunctivitis shigellosa induced by immunization with outer membrane proteins of Shigella spp.

Authors:  G Adamus; M Mulczyk; D Witkowska; E Romanowska
Journal:  Infect Immun       Date:  1980-11       Impact factor: 3.441

9.  Shigella sonnei phase I and phase II: susceptibility to direct serum lysis and opsonic requirements necessary for stimulation of leukocyte redox metabolism and killing.

Authors:  G S Madonna; R C Allen
Journal:  Infect Immun       Date:  1981-04       Impact factor: 3.441

10.  Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine.

Authors:  R E Black; M M Levine; M L Clements; G Losonsky; D Herrington; S Berman; S B Formal
Journal:  J Infect Dis       Date:  1987-06       Impact factor: 5.226

View more
  63 in total

Review 1.  Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Authors:  Myron M Levine; Karen L Kotloff; Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

2.  Characterization of a multicomponent live, attenuated Shigella flexneri vaccine.

Authors:  BreOnna C DeLaine; Tao Wu; Christen L Grassel; Avital Shimanovich; Marcela F Pasetti; Myron M Levine; Eileen M Barry
Journal:  Pathog Dis       Date:  2016-04-21       Impact factor: 3.166

Review 3.  Progress and pitfalls in Shigella vaccine research.

Authors:  Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein; Alessio Fasano; Karen L Kotloff; Myron M Levine
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-02-19       Impact factor: 46.802

4.  An update on vaccines against Shigella.

Authors:  Shai Ashkenazi; Dani Cohen
Journal:  Ther Adv Vaccines       Date:  2013-09

5.  Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers.

Authors:  D Cohen; S Ashkenazi; M Green; Y Lerman; R Slepon; G Robin; N Orr; D N Taylor; J C Sadoff; C Chu; J Shiloach; R Schneerson; J B Robbins
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

6.  Establishment of a Shigella sonnei human challenge model in Thailand.

Authors:  Ladaporn Bodhidatta; Punnee Pitisuttithum; Supat Chamnanchanant; Karen T Chang; Dilara Islam; Valai Bussaratid; Malabi M Venkatesan; Thomas L Hale; Carl J Mason
Journal:  Vaccine       Date:  2012-10-12       Impact factor: 3.641

7.  Recognition of three epitopic regions on invasion plasmid antigen C by immune sera of rhesus monkeys infected with Shigella flexneri 2a.

Authors:  K R Turbyfill; S W Joseph; E V Oaks
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

8.  Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains.

Authors:  A B Hartman; C J Powell; C L Schultz; E V Oaks; K H Eckels
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

9.  Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid.

Authors:  C Y Chu; B K Liu; D Watson; S S Szu; D Bryla; J Shiloach; R Schneerson; J B Robbins
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

10.  O-specific [corrected] polysaccharide conjugate vaccine-induced [corrected] antibodies prevent invasion of Shigella into Caco-2 cells and may be curative.

Authors:  Yehuda Chowers; Joachim Kirschner; Nathan Keller; Iris Barshack; Simon Bar-Meir; Shai Ashkenazi; Rachel Schneerson; John Robbins; Justen H Passwell
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.